VINCRISTINE SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C46H56N4O10.H2O4S
Molecular Weight	923.036
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.[H][C@@]12N3CC[C@@]14C5=CC(=C(OC)C=C5N(C=O)[C@@]4([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]6(C[C@H]7CN(C[C@](O)(CC)C7)CCC8=C6NC9=CC=CC=C89)C(=O)OC

InChI

InChIKey=AQTQHPDCURKLKT-PNYVAJAMSA-N

InChI=1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37-,38+,39+,42-,43+,44+,45-,46-;/m0./s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00541
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/vincristine.html

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.Vincristine was marketed under the brand name Oncovin, but was discontinued. In 2012 the FDA approved a Liposomal formulation of Vincristine, named MARQIBO KIT.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
transformed cell apoptotic process 108 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19137911	Activator 1430
Tubulin beta chain 8 Target ID: P07437 Gene ID: 203068.0 Gene Symbol: TUBB Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00541	Inhibitor 8297
microtubule polymerization 20 Target ID: GO:0046785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10920282	Inhibitor 8297	1.6 µM [IC50]
CCRF-CEM 4 Target ID: CHEMBL382 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22582991	Inhibitor 8297	0.17 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202497s000lbl.pdf	Primary		Approved 8429	Marqibo Approved Use Marqibo® is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Launch Date 2012

C_max

Value	Dose	Co-administered	Analyte	Population
1220 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000PharmR.pdf	2.25 mg/m² steady-state, intravenous dose: 2.25 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:		VINCRISTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
14566 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000PharmR.pdf	2.25 mg/m² steady-state, intravenous dose: 2.25 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered:		VINCRISTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
25% OTHER GOV https://www.medsafe.govt.nz/profs/Datasheet/v/Vincristinesulfatempinj.pdf			VINCRISTINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2.25 mg/m2 1 times / week multiple, intravenous MTD Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 18 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	DLT: Motor polyneuropathy, Seizure... Dose limiting toxicities: Motor polyneuropathy (grade 3, 14.3%) Seizure (grade 4, 14.3%) Hepatotoxicity (grade 4, 14.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	DLT: Neutropenia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 33.3%) Thrombocytopenia (grade 4, 33.3%) Obstipation Myalgia (grade 3, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
2.4 mg/m2 3 times / week multiple, intravenous MTD Dose: 2.4 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704	unhealthy, 32-83 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704	Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.704
2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	Disc. AE: Peripheral neuropathy, Tumor lysis syndrome... AEs leading to discontinuation/dose reduction: Peripheral neuropathy (10%) Tumor lysis syndrome (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8

AEs

AE	Significance	Dose	Population
Motor polyneuropathy	grade 3, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Hepatotoxicity	grade 4, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Seizure	grade 4, 14.3% DLT	2.4 mg/m2 1 times / week multiple, intravenous Studied dose Dose: 2.4 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.4 mg/m2, 1 times / week Co-administed with:: dexamethasone, i.v.(40 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6	unhealthy, 19-62 n = 7 Health Status: unhealthy Condition: Acute lymphoblastic leukemia Age Group: 19-62 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/19708032 Page: p.1,6
Obstipation	DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Myalgia	grade 3, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Neutropenia	grade 4, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Thrombocytopenia	grade 4, 33.3% DLT	2.8 mg/m2 3 times / week multiple, intravenous Highest studied dose Dose: 2.8 mg/m2, 3 times / week Route: intravenous Route: multiple Dose: 2.8 mg/m2, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701	unhealthy, 32-83 n = 3 Health Status: unhealthy Condition: Cancer Age Group: 32-83 Sex: M+F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/10080616 Page: p.701
Peripheral neuropathy	10% Disc. AE	2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8
Tumor lysis syndrome	2% Disc. AE	2.25 mg/m2 1 times / week multiple, intravenous Recommended Dose: 2.25 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 2.25 mg/m2, 1 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8	unhealthy n = 83 Health Status: unhealthy Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) Population Size: 83 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf Page: p.8

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737		substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C19 991 P-gp 1537

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31 Page: 31.0	likely
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31 Page: 31.0	likely
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17029589/	yes
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31; https://pubmed.ncbi.nlm.nih.gov/10613614/ Page: 31.0	yes	yes (co-administration study) Comment: the total area under the plasma concentration-time curve was 43% smaller in patients who were receiving carbamazepine or phenytoin than in the control group; the concomitant use of strong CYP3A inhibitors should be avoided (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin). Similarly, the concomitant use of strong CYP3A inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John’s Wort) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202497Orig1s000ClinPharmR.pdf#page=31; https://pubmed.ncbi.nlm.nih.gov/10613614/ Page: 31.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/15812674/ Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	E375
AbovChem LLC	HY-N0488
BOC Sciences	2068-78-2
BioSynth	Q-201925
Biopurify Phytochemicals	BP1439
Biopurify Phytochemicals	BP1440
Bosche Scientific	V1207
Cayman Chemical	11764
Chem Scene	CS-1778
Hangzhou APIChem Technology	AC-22619
Hangzhou Yuhao Chemical Technology	RT14234
IBScreen	STOCK1N-40733
KeyOrganics	AS-12168
MedChem Express	HY-N0488
MolPort	MolPort-002-519-272
MolPort	MolPort-003-939-860
MolPort	MolPort-035-789-673
Sigma Aldrich	1714007
Sigma Aldrich	V0400000
Sigma Aldrich	V0400000\|SIAL
Sigma Aldrich	V8388\|SIAL
Sigma Aldrich	V8879\|SIGMA
ZINC	ZINC000085537024	http://zinc15.docking.org/substances/ZINC000085537024
eMolecules	32176538
eMolecules	50241482
eMolecules	95704370
mcule	MCULE-1562099693
mcule	MCULE-3827132352

PubMed

Title	Date	PubMed
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.	1992 Feb	1312230
Vincristine neurotoxicity.	1992 Mar	1319399
[Superiority of intrafascicular neurography over conventional nerve conduction studies in evaluating axonal degeneration].	1999 Apr	10363265
Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.	1999 Apr 29	10348353
The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.	2000 Aug	10900222
Bilateral transient hearing loss associated with vincristine therapy: case report.	2000 Dec	11154039
[Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype].	2000 Jul	11778547
Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.	2001	11458812
Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death.	2001 Aug 3	11478917
Adult medulloblastoma: multiagent chemotherapy.	2001 Jan	11305414
Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.	2001 Jul	11438417
Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.	2001 Mar	11255732
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.	2001 May 18	11355937
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.	2002 Aug	12172056
Reversible vincristine-related flaccid paralysis in a child with acute lymphoblastic leukemia.	2002 Aug	12116067
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.	2002 Jun	12225393
Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.	2002 Oct	12358915
Gliomatosis cerebri: molecular pathology and clinical course.	2002 Oct	12325066
Altered temporal pattern of evoked afferent activity in a rat model of vincristine-induced painful peripheral neuropathy.	2003	12710988
Enteropathy-associated T-cell lymphoma of the jejunum complicated with intestinal perforation.	2003 Apr	12854879
[Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma].	2003 Apr	12703998
Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.	2003 Apr	12679647
[Anaphylaxia induced by etoposide--a case report].	2003 Aug	12938279
Toxic neuropathy in patients with pre-existing neuropathy.	2003 Jan 28	12552058
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.	2003 Jul 15	12874004
Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia.	2003 May	12749967
Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.	2003 May	12748258
Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1).	2003 May 13	12731862
The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells.	2003 May 16	12706485
Charcot-Marie-Tooth disease and vincristine.	2003 May-Jun	12756314
Functional expression of the multidrug resistance protein 1 in microglia.	2003 Oct	12893836

Patents

Sample Use Guides

In Vivo Use Guide

Marqibo is liposome-encapsulated vincristine. 2.25 mg/m2 intravenously over 1 hour once every 7 days.

Route of Administration: Intravenous

In Vitro Use Guide

Treatment of macrophage monolayers for 24 h with vincristine (10(-5)-10(-7) M) inhibited the antibody dependent cellular cytotoxicity (ADCC) by PMA stimulated rat macrophages.

Name

Type

Language

VINCRISTINE SULFATE

Official Name

English

VINCRISTINE SULFATE [IARC]

Common Name

English

VINCRISTINI SULFAS [WHO-IP LATIN]

Common Name

English

VINCRISUL

Common Name

English

22-OXOVINCALEUKOBLASTINE SULFATE (1:1) (SALT) [WHO-IP]

Common Name

English

VINCRISTINE SULFATE [MART.]

Common Name

English

37231

Code

English

Leurocristine sulfate (1:1) (salt)

Common Name

English

NSC-67574

Code

English

VINCRISTINE SULFATE [JAN]

Common Name

English

Vincristine sulfate [WHO-DD]

Common Name

English

VINCRISTINE SULFATE [USAN]

Common Name

English

VINCRISTINE SULFATE [EP MONOGRAPH]

Common Name

English

VINCRISTINE SULFATE [USP-RS]

Common Name

English

KYOCRISTINE

Common Name

English

VINCALEUKOBLASTINE, 22-OXO-, SULFATE (1:1) (SALT)

Common Name

English

VINCRISTINE SULFATE [VANDF]

Common Name

English

ONCOVIN

Brand Name

English

VINCRISTINE SULFATE [WHO-IP]

Common Name

English

VINCREX

Brand Name

English

VINCRISTINE SULFATE [MI]

Common Name

English

VINCRISTINE SULPHATE

Common Name

English

NOVOPHARM

Common Name

English

LILLY-37231

Code

English

VINCRISTINE SULFATE [USP MONOGRAPH]

Common Name

English

VINCRISTINE SULFATE [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

259108